Analyst Price Target Update on XOMA Corporation (NASDAQ:XOMA)

XOMA Corporation (NASDAQ:XOMA): 3 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $1.62 in XOMA Corporation (NASDAQ:XOMA). However, the stock price could fluctuate by $ 1.2 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $3 price target with the lower price estimate is calculated at $1

Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, Burns Thomas M., officer (VP, Finance & Chief Financial) of Xoma Corp, unloaded 19,249 shares at an average price of $0.79 on March 22, 2016. The total amount of the transaction was worth $15,207, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

XOMA Corporation (NASDAQ:XOMA) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.0244 points or 3.72% at $0.6309 with 895,599 shares getting traded. Post opening the session at $0.65, the shares hit an intraday low of $0.625 and an intraday high of $0.65 and the price was in this range throughout the day. The company has a market cap of $76 million and the number of outstanding shares have been calculated to be 120,367,541 shares. The 52-week high of XOMA Corporation (NASDAQ:XOMA) is $4.93 and the 52-week low is $0.625.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *